Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 13/20 | 0.54 |
| ▸ | JUN | P05412 | 6/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.54 |
| ▸ | RELA | Q04206 | 6/20 | 0.54 |
| ▸ | ATF1 | P18846 | 8/20 | 0.41 |
| ▸ | XPO1 | O14980 | 5/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10167973 | 0.83 | NFKB1 (0.52) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL6643357 | 0.79 | NFKB1 (0.49) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL4768472 | 0.79 | NFKB1 (0.52) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL30498347 | 0.79 | NFKB1 (0.49) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL17681993 | 0.79 | NFKB1 (0.49) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL721758 | 0.78 | KEAP1 (0.47) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL429969 | 0.78 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL31469871 | 0.78 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL13919647 | 0.76 | XPO1 (0.68) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL1320432 | 0.76 | NFKB1 (0.49) | NFKB1JUNNFKB2RELAATF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663991-B1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | PFIZER PROD INC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-7122670-B2 | Selective synthesis of CF3-substituted pyrimidines | PFIZER INC (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1663991-A1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | Pfizer Products Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050101620-A1 | Selective synthesis of CF3-substituted pyrimidines | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005023780-A1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | PFIZER PRODUCTS INC. (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101620-A1 | Selective synthesis of CF3-substituted pyrimidines | HNRNPH3, HNRNPA3, NUDT1 | NFKB1 2914/4885JUN 2357/4885NFKB2 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.